Teva can pursue migraine patent dispute against Eli Lilly
17-03-2022
Eli Lilly can’t avoid royalties in insulin suit
21-10-2021
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27-03-2019
Michael Vi / Shutterstock.com
Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
ElI Lilly, Teva, sanctions, migraine treatment, Ajovy
